ZIB

Treffer pro Seite

Treffer 1 - 2 | 2 Treffer

Sortierung

Digitale Medien

The 156-in. Cyclotron at Liverpool (1955)

MOORE, M. J.

[s.l.] : Nature Publishing Group

Nature 175 (1955), S. 1012-1015

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1476-4687

Quelle: Nature Archives 1869 - 2009

Thema: Biologie , Chemie und Pharmazie , Medizin , Allgemeine Naturwissenschaft , Physik

Notizen: [Auszug] EARLY in 1948, it was shown that n-mesons could be produced in numbers by the bombardment of matter by a-particles produced in the Berkeley synchrocyclotron, and shortly afterwards it was proved that high-energy protons in the same machine were even more effective. Tho threshold for 7t-production ...

Materialart: Digitale Medien

URL: http://dx.doi.org/10.1038/1751012a0

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Digitale Medien

A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal caner (1995)

Moore, M. J. ; Kaizer, Leonard ; Erlichman, Charles ; [weitere]

Springer

Cancer chemotherapy and pharmacology 37 (1995), S. 86-90

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1432-0843

Schlagwort(e): Key words 5-Fluorouracil ; Interferon ; Colorectal cancer

Quelle: Springer Online Journal Archives 1860-2000

Thema: Medizin

Notizen: Abstract Modulation of 5-fluorouracil (FUra) using leucovorin (LV) is a standard treatment approach in patients with metastatic colorectal cancer. Modulation of FUra with interferon alfa has also shown some promise. Laboratory data have demonstrated increased cytotoxicity when FUra is combined with both LV and interferon. The current study examined the effects of double modulation of FUra using LV and interferon.Patients with measurable advanced colorectal cancer received bolus FUra 375 mg/m2 plus LV 20 mg/m2 daily for 5 days, repeated every 28 days. Recombinant human interferon alfa-2a, 3 million IU/m2 subcutaneously, was given daily on the days of chemotherapy then three times weekly. There was one complete response and nine partial responses (10/41) seen for an overall response rate of 24% (95% CI 12.0–40.0%). Overall, 70% of patients experienced one or more episodes of nonhematologic toxicity of grade 3 or more. Weight loss was common, with a mean decrease of 2.9 kg over the first two months (P〈0.0001). Improvements in tumor-related symptoms were balanced by increased fatigue and a deterioration in body weight and performance status. There was no evidence of progressive changes in FUra metabolism from interferon usage.